Clinical Study | Office of Clinical Research

Pr-001 A Phase 2A Randomized, Parallel Group, Open-Label, Multicenter Study To Assess The Safety And Efficacy Of Different Schedules Of Rrx-001 In The Attenuation Of Oral Mucositis In Patients Receiving Concomitant Chemoradiation For The Treatment Of Loca

Posted Date: Jun 21, 2019

Investigator: Vinita Takiar
Specialties: Cancer, Head and Neck Cancer, Oncology
Type of Study: Drug

The goal of this study is to examine varying dosing schedules of RRx-001 in combination with standard of care for cancers of the oral cavity and oropharynx.

Criteria:

To Be Eligible: Diagnosed With Scc Of The Oropharynx, Age 18 Or Older, Nonpregnant/Breastfeeding, No Prior Radiation To Head And Neck Or Induction Chemotherapy,

Keywords:

Head And Neck Cancer, Oropharangeal, Radiation

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List